While such deregulation may have been imposed to increase competition, it also interferes with the incentives of the participants.
The lack of real oversight, combined with the introduction of unnecessary profit margins and shareholder returns, encourage and enable the participants to act in ways that are harmful to patients.
The truly unfortunate part is that deregulation often takes options and choices away from patients, as an unregulated market’s tendency toward monopoly prevents them from accessing alternatives that may help mitigate or avoid the perverse incentives introduced by quarterly performance targets.